News | August 11, 2024
Merck inks MoU with Aragen to facilitate supply of equipment and technologies for mAb
This accelerates the clinical-to-commercial process timeline and enables customers to develop the right molecule
This accelerates the clinical-to-commercial process timeline and enables customers to develop the right molecule
Both departments will be equipped with specialized professionals and state-of-the-art facilities ensuring the highest standards of care
Relonchem Limited has received Marketing Authorization for the product Levonorgestrel 1.5 mg Tablets from UK MHRA
Boehringer Ingelheim aims to develop this program as a potential key centerpiece component for its immuno-oncology portfolio
Decision on EU marketing authorisation for this population expected by September 2024
Access to breast milk for sick newborns admitted in intensive care units plays a lifesaving role
Giroctocogene fitelparvovec study meets primary and key secondary objectives of superiority compared to prophylaxis
A one-time dose of DURVEQTIX has reduced bleeds post-treatment compared to standard of care with a median annualized bleed rate (ABR) of zero bleeds (range 0 to 9.9)
The partnership will focus on creating capabilities for quickly and accurately processing vast amounts of clinical data
Reported profit after tax declined 19% year-on-year to Rs 76 crores
Subscribe To Our Newsletter & Stay Updated
